Cannabinoids in late-onset Alzheimer's disease

Clinical Pharmacology and Therapeutics
Aia AhmedMgm Olde Rikkert

Abstract

Given the lack of effective treatments for late-onset Alzheimer's disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment of LOAD and other physical conditions that are common in older people. Several in vitro and in vivo studies have demonstrated that cannabinoids can reduce oxidative stress, neuroinflammation, and the formation of amyloid plaques and neurofibrillary tangles, the key hallmarks of LOAD. In addition, in population-based studies, cannabinoids reduced dementia-related symptoms (e.g., behavioral disturbances). The current article provides an overview of the potential of cannabinoids in the treatment of LOAD and related neuropsychiatric symptoms in older people. We also discuss the efficacy, safety, and pharmacokinetics of cannabinoid-based drugs in older people with dementia.

References

Jan 1, 1981·Journal of Psychoactive Drugs·M Touw
Sep 28, 1998·Biochimica Et Biophysica Acta·F BerrenderoJ J Fernández-Ruiz
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C H Ashton
Apr 23, 2002·JAMA : the Journal of the American Medical Association·Kristine YaffeKenneth E Covinsky
May 8, 2002·International Journal of Geriatric Psychiatry·Michal Schnaider BeeriShlomo Noy
Oct 18, 2002·Neuroscience Letters·Nathaniel G N Milton
Apr 6, 2004·Brain Research. Brain Research Reviews·John M McPartland
Feb 3, 2005·JAMA : the Journal of the American Medical Association·Kaycee M SinkKristine Yaffe
Feb 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Belén G RamírezMaría L de Ceballos
Apr 29, 2005·International Journal of Clinical Practice·M A WareG W Guy
May 11, 2005·Neurology·S GilmanUNKNOWN AN1792(QS-21)-201 Study Team
Jan 4, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Giuseppe EspositoTeresa Iuvone
Mar 8, 2006·Psychopharmacology·Sebastian WaltherDieter Kunz
Apr 28, 2006·Geriatric Nursing·Barbara J Zarowitz
May 30, 2006·Cellular and Molecular Life Sciences : CMLS·M van der SteltV Di Marzo
Sep 14, 2006·Pharmacological Reviews·Pál PacherGeorge Kunos
Oct 13, 2006·Journal of Neural Transmission·P EikelenboomJ J M Hoozemans
Dec 5, 2006·Molecular Pharmaceutics·Lisa M EubanksKim D Janda
Sep 28, 2007·The American Journal of Psychiatry·Helen C KalesFrederic C Blow
Dec 18, 2007·International Journal of Geriatric Psychiatry·Michael J Passmore
Feb 29, 2008·Neurobiology of Aging·Paula M CanasRodrigo A Cunha
May 16, 2009·Cancer Letters·Amy AlexanderRhonda J Rosengren
May 22, 2009·Journal of Neurochemistry·John Hardy
Dec 18, 2009·Current Medicinal Chemistry·A CorsonelloR A Incalzi
Apr 1, 2010·Experimental Neurology·Lourdes Ruiz-ValdepeñasJulián Romero
May 14, 2010·Journal of Alzheimer's Disease : JAD·John Xi Chen, Shirley Shidu Yan
Jul 9, 2010·Lancet Neurology·Francesca MangialascheMiia Kivipelto
Nov 3, 2010·Neurochemistry International·Jasinda H LeeMitchell K P Lai
Feb 26, 2011·Molecular Pharmacology·Ana María Martín-MorenoMaría L de Ceballos
Mar 3, 2011·Journal of Clinical Psychopharmacology·Sebastian WaltherWerner Strik
Apr 5, 2011·Brain : a Journal of Neurology·Jan MulderTibor Harkany
Jul 20, 2011·Journal of Psychopharmacology·Tiziana RubinoDaniela Parolaro
Sep 6, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Constantine G LyketsosDavid S Miller
Nov 1, 2011·British Journal of Clinical Pharmacology·Salvatore SalomoneFilippo Drago

❮ Previous
Next ❯

Citations

Mar 25, 2015·Clinical Pharmacology and Therapeutics·B Le Foll, R F Tyndale
Mar 7, 2017·Canadian Journal of Physiology and Pharmacology·Yan Lu, Hope D Anderson
Mar 27, 2018·European Journal of Clinical Investigation·Edward J Calabrese, Alberto Rubio-Casillas
Oct 7, 2018·Journal of the American Geriatrics Society·Ian R ReynoldsGretchen Orosz
Nov 9, 2018·Frontiers in Integrative Neuroscience·Ethan B Russo
Feb 1, 2018·Médecine sciences : M/S·Hélène Gilgenkrantz
Dec 15, 2019·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Anees BahjiEmily R Hawken
Apr 10, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Rui S RodriguesSara Xapelli
Feb 22, 2017·Frontiers in Pharmacology·Georgia Watt, Tim Karl
Feb 20, 2020·Current Medicinal Chemistry·Natália Martins, Isabel C F R Ferreira
Feb 15, 2020·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Javier Fernández-RuizManuel Guzmán
Nov 3, 2020·Journal of Psychiatric Research·Weijing WangDongfeng Zhang
Sep 18, 2021·The Cochrane Database of Systematic Reviews·Dina Bosnjak KuharicLivia Puljak
Feb 11, 2020·Current Medicinal Chemistry·Andrea MastinuAlessandra Gianoncelli
Sep 30, 2021·Journal of Geriatric Psychiatry and Neurology·Katie Stypulkowski, Rachel E Thayer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Cellular and Molecular Medicine
N. Bogdanovic
Journal of the American Medical Directors Association
Donna Masterman
© 2021 Meta ULC. All rights reserved